rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GILD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Gilead Sciences chief comm & corp aff officer Mercier sells $4.7M shares
      Nov 18Investing.comGILD
      Gilead Sciences CFO Dickinson sells $514,410 in stock
      Nov 18Investing.comGILD
      Gilead Sciences Inc. stock outperforms competitors on strong trading day
      Nov 17MarketWatchGILD
      Gilead at Jefferies Global Healthcare Conference: growth broadens
      Nov 17Investing.comGILDJEF
      Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
      Nov 17Yahoo FinanceAMGNGILDMRNAREGN
      Gilead Partners With Generic Manufacturers to Boost Future Access to Experimental Ebola Prevention Drug
      Nov 17BenzingaGILD
      Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
      Nov 17Yahoo FinanceGILD
      Gilead: Growth Supports A Hold Despite A Valuation Premium
      Nov 17Seeking AlphaGILD
      Gilead Sciences (GILD) Grants Royalty Free Ebola Drug Licenses For Lower Income Countries
      Nov 17Yahoo FinanceGILD
      These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 17The Globe and MailGILD
      Gilead signs generic licensing deals for experimental Ebola drug
      Nov 16ReutersGILD
      Gilead signs licensing deals for Ebola drug obeldesivir
      Nov 16Investing.comGILD
      Gilead Sciences director Kelly Kramer sells $1.76 million in stock
      Nov 16Investing.comGILD
      The Zacks Analyst Blog Highlights Home Depot, Gilead Sciences, TotalEnergies, Key Tronic and iPower
      Nov 13Yahoo FinanceGILDIPWKTCCHDTTE
      Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead and AstraZeneca ...

      Compugen Ltd (CGEN) posted $3.8 million in Q3 2026 revenue, completed MAIA-ovarian enrollment with data due by Q1 2027, and holds $117.5 million in cash to fund operations into 2029.

      Nov 12Yahoo FinanceAZNCGENGILD
      Gilead Sciences Inc. stock underperforms Thursday when compared to competitors
      Nov 12MarketWatchGILD
      Top Research Reports for Home Depot, Gilead & TotalEnergies
      Nov 12Yahoo FinanceGILDHDTTE
      Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Nov 12The Globe and MailGILD
      Argus raises Gilead Sciences stock price target on pipeline strength
      Nov 12Investing.comGILD
      Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
      Nov 12Yahoo FinanceGILD
      Lilly, Gilead Face Near-Term Drug Pricing Risks: EXCLUSIVE - Merck & Co (NYSE:MRK), Eli Lilly (NYSE:LLY)
      Nov 11BenzingaGILDLLYMRK
      Gilead Sciences (GILD) Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
      Nov 11Yahoo FinanceGILD
      Gilead Sciences (GILD) After Trial Wins And Raised Guidance Looks Fully Valued
      Nov 11Yahoo FinanceGILD
      iShares Biotechnology ETF (IBB) Adds Gilead and Amgen on Nov. 9
      Nov 11Yahoo FinanceAMGNGILDIBB
      Can Gilead’s Cash Keep Growing?
      Nov 10Yahoo FinanceGILD
      Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch
      Nov 10Yahoo FinanceGILD
      Gilead at Wolfe Healthcare Conference: anito-cel launch in focus
      Nov 10Investing.comGILD
      Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
      Nov 10Yahoo FinanceGILD
      Gilead Sciences EVP sells $557,809 in company stock
      Nov 10Investing.comGILD
      Gilead Sciences Inc. stock rises Monday, still underperforms market
      Nov 9MarketWatchGILD
      Gilead Rival Shoots To Two-Year High On Hepatitis D News

      Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.

      Nov 9Investor's Business DailyGILD
      Gilead Highlights Strong Trial Results in HIV Prevention and Liver Disease
      Nov 9BenzingaGILD
      Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?
      Nov 7Yahoo FinanceGILD
      Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
      Nov 6BenzingaGILD
      Gilead Sciences CEO O’Day sells $19.7 million in company shares
      Nov 6Investing.comGILD
      Gilead seeks wider use for Livdelzi on Phase III liver disease success
      Nov 6Yahoo FinanceGILD
      Gilead presents PBC trial data, plans regulatory discussions
      Nov 5Investing.comGILD
      Did Earnings Beat Just Shift Gilead Sciences' (GILD) Investment Narrative?

      Gilead Sciences reported third quarter 2026 revenue of US$8.3b and raised full year product sales guidance, while also outlining a larger projected GAAP loss tied to sizeable acquired R&D charges and maintaining its quarterly dividend at US$0.82 per share. Alongside the earnings update, Gilead highlighted extensive HIV, liver disease and oncology data readouts, signaling heavy investment in long acting prevention, new treatment regimens and cell therapy that could reshape how its future...

      Nov 5Yahoo FinanceGILD
      Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
      Nov 5Yahoo FinanceGILD
      What Could Go Wrong At Gilead From Here?
      Nov 4Yahoo FinanceGILD
      Gilead Sciences Inc. stock outperforms competitors on strong trading day
      Nov 4MarketWatchGILD
      Gilead to present data on anito-cel, Yescarta at ASH meeting
      Nov 4Investing.comGILD
      Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
      Nov 4Yahoo FinanceGILD
      Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
      Nov 4Yahoo FinanceGILD
      DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
      Nov 4Yahoo FinanceGILD
      Jefferies reiterates Buy on Gilead stock, sees lower IRA impact
      Nov 4Investing.comGILDJEF
      Dr. Reddy's generic targeting Gilead’s Yeztugo approved (GILD)

      Dr. Reddy's Laboratories (RDY) stock gains as the firm wins FDA nod for a generic targeting Yeztugo, an HIV PrEP therapy developed by Gilead (GILD). Read more here.

      Nov 3Seeking AlphaGILD
      Gilead Sciences Stock: Analyst Estimates & Ratings
      Nov 3BarchartGILD
      Gilead Sciences CEO Daniel O’Day sells $5.3M in shares
      Nov 3Investing.comGILD
      Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
      Nov 2AP NewsGILD

      This is the newest page. Registered accounts read further back.